Events Archives - Page 31 of 128

3 minute read

Artelo Biosciences To Present Preclinical Data Showcasing Research On ART26.12 And ART12.11 In Anxiety And Depression At Neuroscience 2023

November 2, 8:54 AM

Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological

ARTL

3 minute read

Teva To Present New Data Supporting Safety, Efficacy And Real-World Effectiveness Of AUSTEDO Tablets At The 2023 HSG Annual Meeting

By Benzinga Newsdesk

November 2, 8:28 AM

92% of patients with Huntington's disease (HD) chorea achieved optimal dosing by week 12 with treatment on the AUSTEDO 4-week patient titration kit according to early results from the START studyAdditional results

TEVA

2 minute read

Corbus Pharmaceuticals Presents Results Of Two Pre-Clinical Studies On Its Anti-αVβ8 Monoclonal Antibody At The 2023 SITC Annual Meeting

By Benzinga Newsdesk

November 2, 8:23 AM

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal

CRBP

3 minute read

Booze And Bud: Friend Or Foe In The Cannabis-Infused Beverage World?

By Joana Scopel

October 31, 8:24 PM

Cannabis-infused beverages are swiftly making their mark alongside traditional alcoholic drinks, and a recent panel discussion at the Benzinga Cannabis Capital Conference shed light on this burgeoning industry.

CURLF

1 minute read

Aura Biosciences To Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan For The First-Line Treatment Of Patients With Early-Stage Choroidal Melanoma At AAO 2023

By Benzinga Newsdesk

October 31, 4:44 PM

Aura Biosciences Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that updated data from

AURA

1 minute read

Pliant Therapeutics Announces Three Presentations At The Annual Meeting Of The Society For Immunotherapy Of Cancer

By Benzinga Newsdesk

October 31, 4:42 PM

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced three

PLRX

1 minute read

Xilio To Host Virtual Investor Conference Call And Webcast On Monday, November 6, 2023 To Review Progress Across Pipeline, Including Phase 1/2 Clinical Data For XTX202, A Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented At The SITC Annual Meetin…

By Benzinga Newsdesk

October 31, 9:22 AM

Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an

XLO

2 minute read

Compugen To Present New Data At SITC 2023 Suggesting Leading Edge Of Anti-IL18 Binding Protein Antibody, COM503, In Treating Cancer

By Benzinga Newsdesk

October 31, 9:20 AM

COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growthAnti-IL-18BP antibody immune modulation is confined to the tumor site expected to have a

CGEN

2 minute read

Iovance Biotherapeutics To Present Clinical And Pre-Clinical Data For Tumor Infiltrating Lymphocyte Therapies At Society For Tumor Immunotherapy Of Cancer’s 38th Annual Meeting

By Benzinga Newsdesk

October 31, 9:20 AM

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today

IOVA

2 minute read

Indaptus Therapeutics To Present Pharmacodynamic Immune And Pharmacokinetic Results With Patients From First Cohort Of Ongoing Phase 1 Study Of Decoy20 At Cancer Immunotherapy Meeting

By Benzinga Newsdesk

October 31, 9:17 AM

Poster to be presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4, 2023 NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) announces it will be

INDP